SCOTTSDALE, Ariz., Oct. 16 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.
In this report, entitled "MedPredict Thought Leader Insight & Analysis: Anxiety & Depression," physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.
"There have been some notable developments in the use of antipsychotics, and special emphasis on new classes -- including CRF and NK antagonists," according to Jeff Berk, MedPredict President. "The thesis of this panel is that there are two types of new drug launches that will be successful in the next five years. The first is augmentation strategies to SSRIs. Today this includes the use of low dose quetiapine. This time frame should also see the approval of the first NK and CRF antagonists." According to this report, monotherapy strategies will find a home mostly in the primary care setting after failure of a generic SSRI. In the community setting, safety will trump efficacy, and a parity claim with an improved side effect profile will win out.
The report also discusses the role of genomics, endophenotypes and biomarkers in the development of pharmacotherapies for depression.
Drugs/Companies mentioned in this report include: Effexor (venlafaxine;
Wyeth), Lexapro (escitalopram; Forest), Pristiq (o-desmethylvenlafaxine;
Wyeth), Cymbalta (duloxetine; Lilly), Wellbutrin (bupropion;
GlaxoSmithKline), Valdoxan (agomelatine; Novartis/Servier), bifeprunox
(Wyeth/Solvay/ Lundbeck), Seroquel (quietiapine; AstraZeneca), amibegron
(Sanofi-Aventis), GSK-561679 (GSK), Pexacerfont (BMS-562086; Bristol-Myers
Squibb), ONO-2333Ms (Ono), casopitant (GlaxoSmithKline), saredutant
Copyright©2007 PR Newswire.
All rights reserved